Literature DB >> 12955305

Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers.

James P Zacny1, Sandra Gutierrez2.   

Abstract

RATIONALE: The subjective, psychomotor, and physiological effects of a widely prescribed and abused prescription opioid, oxycodone, have not been studied in a population of non-drug-abusing people.
OBJECTIVES: To characterize the effects of oxycodone in non-drug-abusing volunteers.
METHODS: Eighteen volunteers participated in a crossover, randomized, double-blind study in which they received, all p.o., placebo, 10 mg oxycodone, 20 mg oxycodone, 30 mg oxycodone, 40 mg morphine, and 2 mg lorazepam. Measures were assessed before and for 300 min after drug administration. End-of-session and 24-h post-session measures were taken to assess residual drug effects and overall subjects' assessments of the drug effects.
RESULTS: Subjective effects of oxycodone were dose related, with the majority of statistically significant effects limited to the two higher doses tested. Oxycodone produced a profile of subjective effects that included both pleasant and unpleasant effects. Morphine in general produced effects similar in magnitude to those of 10 mg and 20 mg oxycodone. Peak liking and drug-wanting ratings were increased by all doses of oxycodone and by morphine, and trough ratings of liking (dislike) were lower in the 20-mg and 30-mg oxycodone conditions, relative to the placebo condition. Post-session ratings of overall liking and drug wanting were not statistically significant, either at the end of the session or 24 h later. Cognitive and psychomotor impairment were obtained with the higher doses of oxycodone, but to a much lesser degree than that of lorazepam. Miosis and exophoria were increased in a dose-related manner by oxycodone.
CONCLUSIONS: Oxycodone produced effects similar to those of other mu opioid agonists. Although oxycodone produced abuse liability-related subjective effects, it also produced unpleasant effects, a phenomenon we have observed in other opioid studies in non-drug-abusing volunteers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955305     DOI: 10.1007/s00213-003-1540-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

Review 1.  Abuse liability studies of opioid agonist-antagonists in humans.

Authors:  K L Preston; D R Jasinski
Journal:  Drug Alcohol Depend       Date:  1991-06       Impact factor: 4.492

Review 2.  Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects.

Authors:  L A Dykstra; K L Preston; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  1997-03       Impact factor: 4.530

3.  Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.

Authors:  James P Zacny
Journal:  Psychopharmacology (Berl)       Date:  2002-10-29       Impact factor: 4.530

4.  Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia.

Authors:  M Silvasti; P Rosenberg; T Seppälä; N Svartling; M Pitkänen
Journal:  Acta Anaesthesiol Scand       Date:  1998-05       Impact factor: 2.105

5.  Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam.

Authors:  K Seppälä; K Korttila; S Häkkinen; M Linnoila
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

Review 6.  The treatment of cancer pain.

Authors:  K M Foley
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

7.  The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated.

Authors:  Fraser B Ross; Maree T Smith
Journal:  Pain       Date:  1997-11       Impact factor: 6.961

8.  Behavioral and physiological effects of remifentanil and alfentanil in healthy volunteers.

Authors:  M L Black; J L Hill; J P Zacny
Journal:  Anesthesiology       Date:  1999-03       Impact factor: 7.892

Review 9.  Performance tests.

Authors:  A Wetherell
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

10.  Measurement of recovery from outpatient general anaesthesia with a simple ocular test.

Authors:  J G Hannington-Kiff
Journal:  Br Med J       Date:  1970-07-18
View more
  47 in total

1.  Assessment of the aversive and rewarding effects of alcohol in Fischer and Lewis rats.

Authors:  Peter G Roma; Wesley W Flint; J Dee Higley; Anthony L Riley
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

2.  Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers.

Authors:  Cynthia M Gooch; Brian C Rakitin; Ziva D Cooper; Sandra D Comer; Peter D Balsam
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

Review 3.  Neuropsychological consequences of opiate use.

Authors:  Staci A Gruber; Marisa M Silveri; Deborah A Yurgelun-Todd
Journal:  Neuropsychol Rev       Date:  2007-08-10       Impact factor: 7.444

4.  Genetic and early environmental contributions to alcohol's aversive and physiological effects.

Authors:  Peter G Roma; Jennifer A Rinker; Katherine M Serafine; Scott A Chen; Christina S Barr; Kejun Cheng; Kenner C Rice; Anthony L Riley
Journal:  Pharmacol Biochem Behav       Date:  2008-06-29       Impact factor: 3.533

Review 5.  Misuse of and dependence on opioids: study of chronic pain patients.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Douglas Gourlay; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

Review 6.  Opioids for managing chronic non-malignant pain: safe and effective prescribing.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Angela Mailis-Gagnon; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

7.  Subjective, psychomotor, and physiological effects of oxycodone alone and in combination with ethanol in healthy volunteers.

Authors:  James P Zacny; Sandra Gutierrez
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

Review 8.  Treatment of brain metastases in lung cancer: strategies to avoid/reduce late complications of whole brain radiation therapy.

Authors:  Mark G Shaw; David L Ball
Journal:  Curr Treat Options Oncol       Date:  2013-12

9.  Effects of oxycodone on brain responses to emotional images.

Authors:  Margaret C Wardle; Daniel A Fitzgerald; Michael Angstadt; Christine A Rabinak; Harriet de Wit; K Luan Phan
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

10.  The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males.

Authors:  David Andrew Tompkins; Michael T Smith; George E Bigelow; Ruin Moaddel; Swarajya Lakshmi Vatem Venkata; Eric C Strain
Journal:  Clin J Pain       Date:  2014-01       Impact factor: 3.442

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.